Alterity Therapeutics Ltd Sustainability Reports
Alterity Therapeutics Limited is a clinical-stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. Its lead drug candidate, ATH434, is designed to reduce brain iron accumulation and inhibit abnormal protein aggregation associated with Parkinsonian disorders like Multiple System Atrophy.
Sector: Manufacturing
Country: Australia
Exchange: Australian Securities Exchange
LEI: 52990045JUZVZ9QL3159
FIGI: BBG001SDZPR5
7 reports from 2010 to 2024
